GSK2374697, a long duration glucagon-like peptide-1 (GLP-1) receptor agonist, reduces postprandial circulating endogenous total GLP-1 and peptide YY in healthy subjects

We investigated the effects of a long‐duration glucagon‐like peptide‐1 (GLP‐1) receptor agonist, GSK2374697, on postprandial endogenous total GLP‐1 and peptide YY (PYY). Two cohorts of healthy subjects, one normal/overweight and one obese, were randomized to receive GSK2374697 2 mg (n = 8 each) or placebo (n = 4 and n = 2) subcutaneously on days 1, 4 and 7. Samples for plasma endogenous GLP‐1 and PYY were collected after breakfast on days −1 and 12. Weighted mean area under the curve (0–4 h) of total GLP‐1 and PYY in treated subjects was reduced compared with placebo. The least squares mean difference for change from baseline was −1.24 pmol/l [95% confidence interval (CI) −2.33, −0.16] and −4.47 pmol/l (95% CI −8.74, −0.20) for total GLP‐1 and PYY, respectively, in normal/overweight subjects (p